

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of: Coleman *et al.*

Patent No: 6,864,226

Issued: March 8, 2005

Title: Endothelial-Monocyte Activating Polypeptide III

REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R. § 1.324

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It has come to the attention of Applicants that Henrik S. Olsen has been erroneously omitted as an inventor of the above-captioned patent. Accordingly, pursuant to 35 U.S.C. § 256 and 37 C.F.R. § 1.324, Applicants respectfully request that the Director correct the inventorship of the above patent by adding Henrik S. Olsen as an inventor.

In support of this request, Patentees submit concurrently herewith:

1. A statement from the added inventor that the inventorship error occurred without deceptive intent on his part;
2. Statements from the current named inventors agreeing to the change of inventorship;
3. An Electronic Fee Transmittal itemizing the processing fee set forth in 37 C.F.R. § 1.20(b); and
4. A statement from the assignee of the original named inventors agreeing to the requested change of inventorship.

As the above submissions fully satisfy the requirements of 37 C.F.R. § 1.324, Applicants respectfully request that the instant request be granted, and that the Director correct the inventorship of the above patent by adding Henrik S. Olsen as an inventor.

If any further action by Applicants is required, please call the undersigned at the phone number provided below. If there are any additional fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: October 18, 2007

/Mark J. Hyman/
Mark J. Hyman (Reg. No. 46,789)
Attorney for Applicants
Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850
Telephone: (240) 314-1224

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:
Coleman et al.

U.S. Patent No.: 6,864,226

Issued: March 8, 2005

For: Endothelial-Monocyte Activating
Polypeptide III


STATEMENT OF TIMOTHY A. COLEMAN

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I agree with the correction of inventorship concerning the above-captioned application adding Henrik S. Olsen on the list of inventors. Timothy A. Coleman, Craig A. Rosen, and Henrik S. Olsen should be listed as the three inventors of the subject matter claimed in the above-identified patent.

Date: 9/20/07



Timothy A. Coleman

18110 Hayloft Drive
Derwood, MD 20855

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:
Coleman et al.

Patent No. 6,864,226

Issued: March 8, 2005

For: Endothelial-Monocyte Activating
Polypeptide III

STATEMENT OF HENRIK S. OLSEN

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I agree with the correction of inventorship concerning the above-captioned application adding Henrik S. Olsen on the list of inventors. Timothy A. Coleman, Craig A. Rosen, and Henrik S. Olsen should be listed as the three inventors of the subject matter claimed in the above-identified patent.

The inventorship error of failing to include Henrik S. Olsen as an inventor of the patent occurred without any deceptive intention on the part of Henrik S. Olsen.

Date: 9/18/07

Henrik S. Olsen
Henrik S. Olsen

182 Kendrick Place #24
Gaithersburg, MD 20878

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:
Coleman et al.

U.S. Patent No.: 6,864,226

Issued: March 8, 2005

For: Endothelial-Monocyte Activating
Polypeptide III

STATEMENT OF CRAIG A. ROSEN

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I agree with the correction of inventorship concerning the above-captioned application resulting in the addition of Henrik S. Olsen on the list of inventors. Timothy A. Coleman, Craig A. Rosen, and Henrik S. Olsen should be listed as the three inventors of the subject matter claimed in the above-identified patent.

Date: _____

9/19/07



Craig A. Rosen

22400 Rolling Hill Lane
Laytonsville, MD 20882

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman *et al.*

Attorney Docket No.: PF206D1

Patent No.: 6,864,226

Issued: March 8, 2005

Title: Endothelial-Monocyte Activating Polypeptide III

**ASSIGNEE STATEMENT UNDER 37 C.F.R. § 3.73(b) AND
AGREEMENT TO CHANGE OF INVENTORSHIP UNDER 37 C.F.R. § 1.324**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. § 3.73(b)

Human Genome Sciences, Inc. ("HGS"), organized and existing under the laws of the State of Delaware, having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850, states that it is the assignee of record of the entire right, title and interest for the above-identified patent by virtue of an assignment from Timothy A. Coleman, Craig A. Rosen, and Henrik S. Olsen, recorded on September 25, 2007, at Reel 019873, Frame 0989. This assignment was directed to Application No. 08/483,534, of which the present patent claims priority, and all continuation and divisional applications thereof.

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of HGS. The undersigned has reviewed all the documents in the chain of title of the above-captioned patent, and, to the best of the undersigned's knowledge and belief, HGS has title in the patent as described above.


Agreement To Change Of Inventorship

HGS hereby agrees with the correction of inventorship concerning the above-captioned patent resulting in the addition of Henrik S. Olsen to the list of inventors, and resulting in Timothy A. Coleman, Craig A. Rosen, and Henrik S. Olsen being listed as the three inventors of the above-captioned patent.

On behalf of Human Genome Sciences, Inc.:

For: Human Genome Sciences, Inc.

Signature: _____



Name: Michele M. Wales

Title: Vice President Intellectual Property

Date: _____

10/29/07